Amit A. Joharapurkar
*
Vrajesh B. Pandya
The final, formatted version of the article will be published soon.
REVIEW article
Front. Nephrol.
Sec. Clinical Research in Nephrology
Volume 4 - 2024 |
doi: 10.3389/fneph.2024.1459425
Desidustat: A novel PHD inhibitor for the treatment of CKD-induced anemia
Provisionally accepted- Zydus Cadila, Ahmedabad, India
Desidustat is a small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) discovered and developed by Zydus Lifesciences for the treatment of anemia associated with chronic kidney disease (CKD). This review summarizes the preclinical and clinical profile of desidustat which led to its approval and clinical use in India.
Keywords: Prolyl hydroxylase inhibitor, HIF, chronic kidney disease-induced anemia, hepcidin, Hemoglobin
Received: 04 Jul 2024; Accepted: 02 Oct 2024.
Copyright: © 2024 Joharapurkar, Pandya, Patel, Jain and Desai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Amit A. Joharapurkar, Zydus Cadila, Ahmedabad, India
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.